Can low omega-3 status reduce the body's ability to actively turn off inflammation even when CRP is normal?

The synthesis of specialized pro-resolving mediators (SPMs) from omega-3 fatty acids represents a critical shift in our understanding of inflammation, moving from a model of passive decay to one of active biochemical termination.

Mechanistic basis of inflammation resolution

EPA and DHA are the primary precursors for four major families of SPMs: resolvins (E-series from EPA; D-series from DHA), protectins, and maresins. These bioactive lipids are synthesized through stereoselective enzymatic pathways involving 5-, 12-, and 15-lipoxygenases (LOX) and cyclooxygenase-2 (COX-2).

• Active termination: SPMs bind to specific G-protein-coupled receptors (such as ChemR23, ALX/FPR2, and GPR32) to actively signal the end of the inflammatory response.
• Cellular actions: Unlike anti-inflammatory drugs that merely block the "on" switch, SPMs inhibit further neutrophil recruitment, promote the apoptosis of existing neutrophils, and stimulate macrophages to clear cellular debris and apoptotic cells (a process known as efferocytosis). This shifting of the macrophage phenotype from a pro-inflammatory (M1) to a pro-resolving (M2) state is essential for returning tissue to homeostasis.

Resolution capacity vs. systemic markers

C-reactive protein (CRP) is a clinical marker of the acute-phase inflammatory response—essentially the intensity of the "on" signal. It does not, however, measure the efficiency of the "off" switch.

• Substrate availability: Clinical data suggests that resolution capacity is substrate-dependent. A low Omega-3 Index limits the pool of EPA and DHA available for rapid conversion into SPMs during an inflammatory challenge.
• The CRP disconnect: Research using lipidomics indicates that individuals can exhibit a "resolution deficit"—low levels of circulating resolvins and protectins—even when CRP is within the normal clinical range (<1.0–3.0 mg/L). This suggests that a person may have low baseline systemic inflammation but still lack the necessary lipid reserves to efficiently terminate an inflammatory event once it is triggered.

Bottom line

EPA and DHA are essential substrates for "turning off" inflammation through SPM synthesis. Because CRP measures pro-inflammatory activity rather than resolution efficiency, a normal CRP level does not guarantee that a patient has sufficient omega-3 status to mount an effective resolution response.